Literature DB >> 7864963

Oral pamidronate in refractory Paget's disease.

E J Roldán.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7864963     DOI： 10.1007/bf00425882

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN： 0171-967X            Impact factor:   4.333


× No keyword cloud information.
  7 in total

Review 1.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

2.  Pamidronate sodium and calcitonin-resistant Paget's disease. Immediate response in a patient.

Authors:  S Drake; J D Massie; A E Postlethwaite; G M Palmieri
Journal:  Arch Intern Med       Date:  1989-02

3.  Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).

Authors:  H I Harinck; S E Papapoulos; H J Blanksma; A J Moolenaar; P Vermeij; O L Bijvoet
Journal:  Br Med J (Clin Res Ed)       Date:  1987-11-21

4.  Treatment of Paget's bone disease with a bisphosphonate.

Authors:  G A Fromm; L Plantalech; C Casco; D González; C A Mautalen
Journal:  Medicina (B Aires)       Date:  1984       Impact factor: 0.653

5.  Treatment of Paget's bone disease with the bisphosphonate APD.

Authors:  C A Mautalen
Journal:  Henry Ford Hosp Med J       Date:  1983

6.  Pamidronate is effective for Paget's disease of bone refractory to conventional therapy.

Authors:  S J Wimalawansa; R D Gunasekera
Journal:  Calcif Tissue Int       Date:  1993-10       Impact factor: 4.333

7.  [Amino-hydroxy-propylidene biphosphonate in the treatment of Paget's disease resistant to calcitonin and/or etidronate].

Authors:  L Miravet; D Kuntz
Journal:  Rev Rhum Mal Osteoartic       Date:  1989-03-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.